Cargando…

A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats

Aim: Nuclear factor kappa B (NF-κB) is known to play an important role in the inflammatory process which takes place after ischemic stroke. The major objective of the present study was to examine the effects of MEDS-23, a potent inhibitor of NF-κB, on clinical outcomes and brain inflammatory markers...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubin, Elina, Pippione, Agnese C., Boyko, Matthew, Einaudi, Giacomo, Sainas, Stefano, Collino, Massimo, Cifani, Carlo, Lolli, Marco L., Abu-Freha, Naim, Kaplanski, Jacob, Boschi, Donatella, Azab, Abed N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773493/
https://www.ncbi.nlm.nih.gov/pubmed/35053779
http://dx.doi.org/10.3390/brainsci12010035
_version_ 1784636104441331712
author Rubin, Elina
Pippione, Agnese C.
Boyko, Matthew
Einaudi, Giacomo
Sainas, Stefano
Collino, Massimo
Cifani, Carlo
Lolli, Marco L.
Abu-Freha, Naim
Kaplanski, Jacob
Boschi, Donatella
Azab, Abed N.
author_facet Rubin, Elina
Pippione, Agnese C.
Boyko, Matthew
Einaudi, Giacomo
Sainas, Stefano
Collino, Massimo
Cifani, Carlo
Lolli, Marco L.
Abu-Freha, Naim
Kaplanski, Jacob
Boschi, Donatella
Azab, Abed N.
author_sort Rubin, Elina
collection PubMed
description Aim: Nuclear factor kappa B (NF-κB) is known to play an important role in the inflammatory process which takes place after ischemic stroke. The major objective of the present study was to examine the effects of MEDS-23, a potent inhibitor of NF-κB, on clinical outcomes and brain inflammatory markers in post-ischemic stroke rats. Main methods: Initially, a Toxicity Experiment was performed to determine the appropriate dose of MEDS-23 for use in animals, as MEDS-23 was analyzed in vivo for the first time. We used the middle cerebral artery occlusion (MCAO) model for inducing ischemic stroke in rats. The effects of MEDS-23 (at 10 mg/kg, ip) on post-stroke outcomes (brain inflammation, fever, neurological deficits, mortality, and depression- and anxiety-like behaviours) was tested in several efficacy experiments. Key findings: MEDS-23 was found to be safe and significantly reduced the severity of some adverse post-stroke outcomes such as fever and neurological deficits. Moreover, MEDS-23 significantly decreased prostaglandin E2 levels in the hypothalamus and hippocampus of post-stroke rats, but did not prominently alter the levels of interleukin-6 and tumor necrosis factor-α. Significance: These results suggest that NF-κB inhibition is a potential therapeutic strategy for the treatment of ischemic stroke.
format Online
Article
Text
id pubmed-8773493
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87734932022-01-21 A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats Rubin, Elina Pippione, Agnese C. Boyko, Matthew Einaudi, Giacomo Sainas, Stefano Collino, Massimo Cifani, Carlo Lolli, Marco L. Abu-Freha, Naim Kaplanski, Jacob Boschi, Donatella Azab, Abed N. Brain Sci Article Aim: Nuclear factor kappa B (NF-κB) is known to play an important role in the inflammatory process which takes place after ischemic stroke. The major objective of the present study was to examine the effects of MEDS-23, a potent inhibitor of NF-κB, on clinical outcomes and brain inflammatory markers in post-ischemic stroke rats. Main methods: Initially, a Toxicity Experiment was performed to determine the appropriate dose of MEDS-23 for use in animals, as MEDS-23 was analyzed in vivo for the first time. We used the middle cerebral artery occlusion (MCAO) model for inducing ischemic stroke in rats. The effects of MEDS-23 (at 10 mg/kg, ip) on post-stroke outcomes (brain inflammation, fever, neurological deficits, mortality, and depression- and anxiety-like behaviours) was tested in several efficacy experiments. Key findings: MEDS-23 was found to be safe and significantly reduced the severity of some adverse post-stroke outcomes such as fever and neurological deficits. Moreover, MEDS-23 significantly decreased prostaglandin E2 levels in the hypothalamus and hippocampus of post-stroke rats, but did not prominently alter the levels of interleukin-6 and tumor necrosis factor-α. Significance: These results suggest that NF-κB inhibition is a potential therapeutic strategy for the treatment of ischemic stroke. MDPI 2021-12-28 /pmc/articles/PMC8773493/ /pubmed/35053779 http://dx.doi.org/10.3390/brainsci12010035 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rubin, Elina
Pippione, Agnese C.
Boyko, Matthew
Einaudi, Giacomo
Sainas, Stefano
Collino, Massimo
Cifani, Carlo
Lolli, Marco L.
Abu-Freha, Naim
Kaplanski, Jacob
Boschi, Donatella
Azab, Abed N.
A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats
title A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats
title_full A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats
title_fullStr A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats
title_full_unstemmed A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats
title_short A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats
title_sort new nf-κb inhibitor, meds-23, reduces the severity of adverse post-ischemic stroke outcomes in rats
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773493/
https://www.ncbi.nlm.nih.gov/pubmed/35053779
http://dx.doi.org/10.3390/brainsci12010035
work_keys_str_mv AT rubinelina anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT pippioneagnesec anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT boykomatthew anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT einaudigiacomo anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT sainasstefano anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT collinomassimo anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT cifanicarlo anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT lollimarcol anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT abufrehanaim anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT kaplanskijacob anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT boschidonatella anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT azababedn anewnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT rubinelina newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT pippioneagnesec newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT boykomatthew newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT einaudigiacomo newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT sainasstefano newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT collinomassimo newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT cifanicarlo newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT lollimarcol newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT abufrehanaim newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT kaplanskijacob newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT boschidonatella newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats
AT azababedn newnfkbinhibitormeds23reducestheseverityofadversepostischemicstrokeoutcomesinrats